my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
18-01-2007: Genizon BioSciences announced a license and collaboration agreement with Pfizer Inc. for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights.
Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed.
The collaboration involves discovery of diagnostic markers from three ongoing genome-wide association studies of the Quebec Founder Population using Genizon's proprietary technology platform. The collaboration will expand these discoveries by including results with those from genome-wide association studies from general populations.
Watchlist
This is where you can add this news to your personal favourites
SFJ Pharmaceuticals and Pfizer to co-develop dacomitinib as treatment for non-small cell lung cancer
The SFJ Pharmaceuticals Group (SFJ), announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer’s investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804). The tria ... more
Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive rig ... more
Ablynx regains rights from Pfizer to nanobodies targeting TNF-alpha
Ablynx announced that it has regained worldwide rights from Pfizer Inc. to develop and commercialise Nanobodies targeting TNF-alpha. These rights include the product ATN-103, for which positive proof-of-concept data from a Phase II trial in rheumatoid arthritis (RA) were announced in May of ... more
Genizon BioSciences Collaborating with NDEI to Enhance Gene Discovery Findings in Schizophrenia
Genizon BioSciences Inc. and Neuropsychiatrie, Decouverte & Innovation Inc. (NDEI) announced an agreement under which the groups will collaborate to enhance and potentially add to discoveries made by Genizon early this year in a genome-wide association study of schizophrenia. Genizon's stud ... more
Genizon BioSciences Publishes Novel Genes for Crohn's Disease
Genizon BioSciences announced publication in Proceedings of the National Academy of Sciences of four novel loci in Crohn's disease, in addition to confirmation of three known Crohn's disease genes. These discoveries are derived from a genome-wide association study in the Quebec Founder Popu ... more
Genizon BioSciences announced a license and collaboration agreement with Pfizer Inc. for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights. Under the terms of the agreemen ... more
Genizon BioSciences Inc., founded in 1999, is the only source for GeneMaps-comprehensive maps of genes, genetic markers, biochemical pathways and drug targets that are unequivocally involved in causing human disease-accelerating the development of safer, more effective medicines. GeneMaps a ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
